Triumph Capital Management’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$698K Buy
1,656
+12
+0.7% +$4.78K 0.12% 181
2026
Q2
$595K Sell
1,644
-3
-0.2% -$1.03K 0.11% 192
2026
Q1
$579K Buy
1,647
+87
+6% +$31K 0.12% 167
2025
Q4
$511K Buy
1,560
+17
+1% +$5.39K 0.11% 168
2025
Q3
$435K Buy
1,543
+569
+58% +$165K 0.12% 187
2025
Q2
$272K Buy
+974
New +$276K 0.08% 239
2022
Q1
– Sell
-2,776
Closed -$625K – 200
2021
Q4
$625K Sell
2,776
-101
-4% -$21.3K 0.27% 89
2021
Q3
$612K Buy
2,877
+315
+12% +$72.5K 0.29% 93
2021
Q2
$627K Buy
+2,562
New +$630K 0.37% 67

Other funds holding AMGN

Triumph Capital Management's AMGN Position: Q3 2026 in Review

Triumph Capital Management increased its Amgen (AMGN) stake by 0.73% in Q3 2026, buying an estimated $4.78K and bringing the position to 1,656 shares worth $698K. The position accounts for 0.12% of the portfolio, ranked #181.

Triumph Capital Management first reported a position in AMGN in Q2 2021 and has held it in 9 quarters since. 3,272 funds tracked by Wall St. Rank hold AMGN as of Q3 2026.

  • Triumph Capital Management held 1,656 shares of Amgen worth $698K as of Q3 2026.
  • Triumph Capital Management bought 12 Amgen shares in Q3 2026, an estimated $4.78K.
  • Amgen made up 0.12% of Triumph Capital Management's portfolio in Q3 2026, its #181 holding.
  • Triumph Capital Management first reported a position in Amgen in Q2 2021 and has held it in 9 quarters since.
  • 3,272 funds tracked by Wall St. Rank held Amgen as of Q3 2026.

Based on Triumph Capital Management's 13F filing for Q3 2026, filed 14 Oct 2026.